These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19356609)

  • 1. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice.
    Deng Y; Zhang K; Tan W; Wang Y; Chen H; Wu X; Ruan L
    Vaccine; 2009 Mar; 27(15):2085-8. PubMed ID: 19356609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice.
    Pancholi P; Perkus M; Tricoche N; Liu Q; Prince AM
    J Virol; 2003 Jan; 77(1):382-90. PubMed ID: 12477843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes.
    Shi L; Liu S; Fan GX; Sheng L; Ren HX; Yuan YK
    Viral Immunol; 2006; 19(4):702-11. PubMed ID: 17201665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.
    Desjardins D; Huret C; Dalba C; Kreppel F; Kochanek S; Cosset FL; Tangy F; Klatzmann D; Bellier B
    J Gene Med; 2009 Apr; 11(4):313-25. PubMed ID: 19248137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
    Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
    Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.
    Saeedi A; Ghaemi A; Tabarraei A; Moradi A; Gorji A; Semnani S; Soleimanjahi H; Adli AH; Hosseini SY; Vakili MA
    Virus Genes; 2014 Aug; 49(1):11-21. PubMed ID: 24752903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine.
    Polakos NK; Drane D; Cox J; Ng P; Selby MJ; Chien D; O'Hagan DT; Houghton M; Paliard X
    J Immunol; 2001 Mar; 166(5):3589-98. PubMed ID: 11207320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.
    Lin Y; Kwon T; Polo J; Zhu YF; Coates S; Crawford K; Dong C; Wininger M; Hall J; Selby M; Coit D; Medina-Selby A; McCoin C; Ng P; Drane D; Chien D; Han J; Vajdy M; Houghton M
    J Virol; 2008 Aug; 82(15):7492-503. PubMed ID: 18508900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two HCV vaccines based on adeno-associated virus vectors elicited durable and effective immune responses in mice].
    Deng Y; Zhang K; Chen H; Liu HM; Wu XB; Ruan L; Tan WJ
    Bing Du Xue Bao; 2009 Jul; 25(4):261-6. PubMed ID: 19769158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice.
    Ghorbani M; Nass T; Azizi A; Soare C; Aucoin S; Giulivi A; Anderson DE; Diaz-Mitoma F
    Viral Immunol; 2005; 18(4):637-48. PubMed ID: 16359230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant.
    Hartoonian C; Sepehrizadeh Z; Mahdavi M; Arashkia A; Jang YS; Ebtekar M; Yazdi MT; Negahdari B; Nikoo A; Azadmanesh K
    Mol Biol Rep; 2014 Sep; 41(9):5943-52. PubMed ID: 24972567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.